Cheapest One Way flight of a Month
Cheapest One Way flight of a Day
Cheapest Round Trip flight of a Month
Cheapest Round Trip flight of a Day
So .. the proposed body is nothing but an attempt to mimic the formality of smaller entities finally emerged in the sister countries. As for the topic This body represents only enjoyed plenty of pharmaceutical entities, monitoring and research, authentic and ancient and the list. While this acquisition does not offer a new actual tasks between what is there, but it leads to practically wasted intensive time and effort and money, both in the development of administrative and financial system particularly disparate entities in administrative and financial systems, or to get a piece of land over 50 acres, and the establishment of new facilities it ... etc. It was in Egypt surpluses in money and time to spend in vain to establish and construction of what is already. As for the issue of subordination of this body directly to the Prime Minister, this is a strange, as in all countries of the world do not follow the medication bodies other than the Ministry of Health, not in the United States, Jordan, England, Japan or any other country (and with the exception of completely individual cases do not represent approach any degree). The project submitted is therefore not only an ambitious Asthawwavea both government entities in the pharmaceutical or authoritarian direct relationship with the Prime Minister. While this is not addressed to any formulations or visions or notices related to the development of the special availability of the drug to patients or the pharmaceutical industry to develop pharmaceutical policy. It is worth to note here that the progress achieved to entities and functions are either pharmacological or non-pharmacological depend first and foremost, and before and after Titles on systemic considerations. That general systemic such as the environment and the types of values and principles declared and undeclared relations. Those that control the kinetics and the activities of the futures system. *** 2 issue of liberalization of drug pricing: In this regard it can be referred to three things. First, the drug in all countries of the world, especially in developed countries, is subject to strict regulations for pricing. Secondly, the pricing multiple mechanisms, which is linked in part to systems of health care (health insurance funds and treatment ... etc). The third thing is that the only major country that is witnessing a great deal of liberalization of drug pricing is the United States, and therefore, a large percentage of its citizens suffer from the high cost of medication. This phenomenon is caused by the dominance of major US companies Mtadiat sexual (and well-known role in the presidential election). In confronting some US states have seen a sharp rejection of the position of the anti-pricing on the part of companies. This refusal has reached the extent of forcing companies claim to practice the «Astrepettaz», so erosion of their economies and finances in relation to the claims of the enormous rise in the cost of research. Also Astsdr Congress finally a decision ensures for pharmacists to import drugs from Canada, where prices are much lower. Thus, the claim in Egypt liberalization of drug pricing becomes completely bizarre behavior, compared to what prevails the world, in line with the medicine as a commodity of a special type. Something else, that Egyptian companies have no justification, even my imagination allows her claim liberalization of pricing, they are not doing research to find a new drug substance. Another reason some people to pay claim to raise prices, which is that the export of Egyptian medicine is the same price in the Egyptian market due to the terms of importing countries and which require the purchase of medicine in the same price in the country of origin (ie Egypt), where prices are usually lower than other markets. Solution to this problem requires a lot of creative marketing, without the need to liberalize pricing. It is a subject that needs to addressed in a separate shrine. On the other hand, some of those in charge of the industry are demanding install lotions similar price (called Generics which is as efficient lotion foreign mother «patent holder») so sold at a price less than the price of the medicine the mother only as much as 20%. In fact, lotions similar prices could fall by more than 20% of the preparation compared to the foreign parent. Therein lies a lesson in real costs. At the same time there is no justification for installing lotions similar prices, which presupposes the existence of competition in prices in favor of the system, drug and in favor of the consumer. Also you can put a ceiling on the price of similar formulations, and be for companies the freedom to determine the price you see at or below this ceiling. This, it is appropriate to reduce the price gradually in line with what occurs to the input costs (especially raw materials) from the drop.
